Following the PRISMA reporting guidelines, we conducted a systematic review to evaluate all clinical and experimental studies published in the literature correlating GH and IGF-1 to inflammation and fibrosis in NAFLD and NASH. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.